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BACKGROUND To cope with the emergence of multidrug-resistant tuberculosis (MDR-TB), new molecular methods that can 
routinely be used to screen for a wide range of drug resistance related genetic markers in the Mycobacterium tuberculosis 
genome are urgently needed.
OBJECTIVE To evaluate the performance of multiplex ligaton-dependent probe amplification (MLPA) against Genotype® 
MTBDRplus to detect resistance to isoniazid (INHr) and rifampicin (RIFr).
METHOD 96 culture isolates characterised for identification, drug susceptibility testing (DST) and sequencing of rpoB, katG, 
and inhA genes were evaluated by the MLPA and Genotype®MTBDRplus assays.
RESULTS With sequencing as a reference standard, sensitivity (SE) to detect INHr was 92.8% and 85.7%, and specificity (SP) 
was 100% and 97.5%, for MLPA and Genotype®MTBDRplus, respectively. In relation to RIFr, SE was 87.5% and 100%, and SP 
was 100% and 98.8%, respectively. Kappa value was identical between Genotype®MTBDRplus and MLPA compared with the 
standard DST and sequencing for detection of INHr [0.83 (0.75-0.91)] and RIFr [0.93 (0.88-0.98)].
CONCLUSION Compared to Genotype®MTBDRplus, MLPA showed similar sensitivity to detect INH and RIF resistance. The results 
obtained by the MLPA and Genotype®MTBDRplus assays indicate that both molecular tests can be used for the rapid detection of 
drug-resistant TB with high accuracy. MLPA has the added value of providing information on the circulating M. tuberculosis lineages.
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Tuberculosis (TB), despite being a curable infectious 
disease, persists as a global health problem that affects 
millions of people each year (WHO 2015). Drug-resist-
ant and multidrug-resistant tuberculosis (DR/MDR-TB) 
have increased worldwide, demanding the development 
of new drug resistance detection assays. The early de-
tection of mycobacterial clades can also support timely 
patient management, as some spoligofamilies have been 
associated with outbreaks, multidrug resistance or more 
aggressive forms of TB disease (Narvskaya et al. 2002, 
Gomes et al. 2012, Dalla Costa et al. 2015).
In some metropolitan Brazilian regions, increased 
rates of treatment default associated with increased 
rates of MDR-TB cases have been observed (Micheletti 
et al. 2014). As effective control of TB and MDR-TB is 
based on the rapid detection of Mycobacterium tuber-
culosis and drug resistance followed by appropriate and 
effective treatment, innovative and rapid diagnostic ap-
proaches and methods are urgently needed. This is es-
pecially true for difficult to manage TB cases, such as 
recurrence cases, relapse, treatment dropout or MDR 
suspicion, to ensure rapid and correct treatment deci-
sions. Current molecular methods based on nucleic 
acid amplification allow identification of clustered ge-
nomic mutations and single nucleotide polymorphisms 
(SNPs) associated with drug resistance, particularly 
resistance to rifampicin (RIF) and/or isoniazid (INH); 
at present the two most important drugs of the standard 
first line treatment for TB (Steingart et al. 2014). The 
Genotype®MTBDRplus assay has been validated and it 
is currently in use in several countries, providing appro-
priate results for drug resistance detection (Schouten et 
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al. 2002, Simons et al. 2015). However, no epidemiologi-
cal information on the M. tuberculosis lineage is pro-
vided by this test. Thus, assays able to test for genome 
dispersed molecular characteristics in a single step are 
appealing and the multiplex ligation-dependent probe 
amplification (MLPA) technique is able to achieve the 
above-mentioned objective (Bergval et al. 2008). MLPA 
is a molecular method that allows simultaneous multi-
plex detection of a large number of SNPs and/or genetic 
markers by amplification of sequence-specific MLPA 
probes rather than the target DNA, without loss of am-
plification efficiency, as observed in a regular multiplex 
polymerase chain reaction (PCR) with too many ampli-
fication targets (Schouten et al. 2002). The presence of 
an MLPA product indicates the presence of the corre-
sponding targeted SNP or genetic marker.
This study evaluates the ability of a highly-multiplexed 
MLPA assay designed to detect an extended number 
of mutations in different M. tuberculosis lineages iso-
lated from Brazilian patients (Bergval et al. 2008). This 
MLPA assay was compared with the WHO-endorsed 
Genotype®MTBDRplus assay, using DNA sequencing and 
conventional drug susceptibility testing (DST) as reference 
gold-standard methods for the genotypic and phenotypic 
characterisation of drug resistance in these strains.
MATERIALS AND METHODS
Setting and routine laboratory procedures - In a retro-
spective study carried out at a reference TB hospital and 
secondary Health Unit in the Rio de Janeiro city, Brazil, 
between January 2004 and July 2006, 96 M. tuberculo-
sis isolates were obtained (one sample per patient) on the 
basis of routine testing. The isolates were confirmed as 
containing acid-fast bacilli by microscopy detection on 
Ziehl-Neelsen stained slides prepared from the cultures in 
Lowenstein-Jensen medium. Standard bacteriological and 
biochemical tests were performed for differentiation of 
species within the M. tuberculosis complex (MTBC) and 
mycobacteria other than tuberculosis (MOTT), includ-
ing biochemical testing for niacin, paranitrobenoic acid 
(PNB) and tiofeno-2-carboxylic acid hydrazine (TCH) 
(MS 2010). Subsequently, the isolates were submitted to 
DST using the proportion method on Lowenstein-Jensen 
solid media (Canetti et al. 1969), following the Brazilian 
Ministry of Health recommended breakpoints for M. tu-
berculosis DST on solid media [isoniazid 0,2 µg/mL; eth-
ambutol (EMB) 2 µg/mL; streptomycin 4 µg/mL; pyra-
zinamide (PZA) 25 µg/mL] (MS 2010).
MLPA design of probes - The probes used were as pre-
viously published and described by Bergval et al (2008), 
with exception the IS6110 probe. In summary: seventeen 
discriminatory markers were selected, and MLPA probes 
were designed accordingly, to provide information about 
drug resistance, principal genotypic group (PGG), and 
(mycobacterial) species (Table I) (Bergval et al. 2008). 
(i) Drug resistance markers (targeted by probes rpoB-
522, rpoB-526G, rpoB- 526T, rpoB-531, rpoB-176, inhA-
15, katG-315, and embB-306). Probe embB-306 targets 
the wild-type sequence, since many different base pair 
changes can occur in this codon. (ii) Genotypic mark-
ers (gyrA codon 95, katG codon 463) to discriminate be-
tween the three PGGs. (iii) The mutT2 codon 58, mutT4 
codon 48, ogt -12, ogt-37 and ogt-15 to identify putative 
virulent strains, such as the various Beijing and Haar-
lem lineages, respectively (Table I). (iv) Discriminatory 
region (specific to members of the MTBC): 16S rRNA 
gene. (v) Probe targeting TbD1: a region that is absent in 
the genome of “modern” M. tuberculosis strains but pres-
ent in all other members of the MTBC.
Genotypic characterisation - Genomic bacterial 
DNA was extracted from M. tuberculosis cultures ac-
cording to a standard protocol described by van Soolin-
gen et al. (1994). Spoligotyping was performed according 
to Gomgnimbou et al. (2013), using a microbead-based 
DNA chip read on a MagPix system (Luminex, Austin, 
TX). The online database SITVIT WEB (Demay et al. 
2012) was used to compare the results with the interna-
tional shared spoligotypes.
DNA sequencing procedures - The key genomic re-
gions involved in the INH resistant phenotype (katG and 
inhA genes) and RIF resistant phenotype (rpoB gene) 
were amplified and sequenced according to protocols 
previously published (Dalla Costa et al. 2009), respec-
tively. Briefly the sequencing amplifications were car-
ried out in an Applied Biosystems® Veriti® 96-Well 
thermo cycler (Thermo Fischer Scientific, California, 
EUA) as follows: 94ºC for 2 min, 55ºC for 1 min, and 
72ºC for 2 min, for 30 cycles. Amplification products 
were analysed by electrophoresis in 1.5% agarose gels, 
purified PCR products were purified with the polyethyl-
ene glycol method and sequenced by using the Big Dye 
Terminator Cycle Sequencing v 3.1 Kit (Applied Biosys-
tems, Foster City, CA, USA) in the ABI Prism 3130xl 
DNA Sequencer (Applied Biosystems).
GenoType® MTBDRplus assay - The Genotype® 
MTBDRplus assay was carried out according to the 
manufacturer’s instructions [Hain Lifescience, Nehren, 
Germany, (Crudu et al. 2012)].
MLPA analysis - All MLPA reagents were manufac-
tured and supplied by MRC-Holland (Amsterdam, The 
Netherlands). The fragments were analysed using an 
ABI 3130xl Genetic Analyzer (Applied Biosystem, Fos-
ter City, CA, USA) capillary electrophoresis instrument. 
The evaluation of these fragments was performed using 
GeneMapper, software version 3.2 (Applied Biosystem, 
Foster City, CA, USA).
Statistical analyses - Statistical analysis was per-
formed using the SPSS v.21 statistical program (SPSS 
Ins. Chicago, IL, USA). Agreement between the meth-
ods was evaluated using the kappa score.
RESULTS
Phenotypic Resistance - From the 96 samples tested, 
82 were isoniazid-susceptible (INH-S), 14 were isoniazid-
resistant (INH-R), 88 were rifampicin-susceptible (RIF-S) 
and eight were rifampicin-resistant (RIF-R), by the stan-
dard DST performed by the proportion method (Canetti et 
al. 1969). Associated INH and RIF resistance was found 
in six samples, defined as MDR-TB strains (Table II).
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Relation between phenotypic resistance and mutations 
in drug-resistance targets for INH and RIF - From the 14 
INH resistant strains characterised by the standard DST 
test, 13 carried a S315T (AGC-ACC) mutation; one carried 
an inhA -15C →T mutation (Table II). Mutation S531L in 
the rpoB gene was identified in all of phenotypic RIF-resis-
tant samples. From these, three had also a second mutation 
in the codon D516V (GAC-GTC) and one had the aggrega-
tion of a third mutation in codon H526Y (CAC-TAC). All 
the samples classified as MDR-TB by the phenotypic DST 
test were confirmed by sequencing (Table II).
Spoligotyping - Spoligotyping using the Luminex 
microbead-based allowed identification of M. tuber-
culosis lineages for 93 of the 96 isolates studied: 58% 
were Latin American Mediterranean (LAM), 22% Euro 
American, 15.5% Haarlem, and 2% X lineage. Three of 
them had indeterminate results. Beijing clade was absent 
in this collection of samples.
MLPA - The identification probe 16SrRNA gave a 
signal in all samples. The genotype markers probe katG-
463 and gyrA-95 also gave a signal in all samples. The 
TbD1 probe was ligated in most of the samples, indicat-
ing that the TbD1 fragment was absent and most strains 
were “modern” genotypes, as this probe targets the 
flanking regions of the deleted TbD1 fragment. The ogt 
-15 identified all the Haarlem strains that were classified 
as Haarlem by spoligotyping. No Beijing family strains 
were identified in this collection of M. tuberculosis by 
MLPA or spoligotyping. Therefore, the sensitivity of 
probes ogt-12, ogt-37, mutT2-58 and mutT4-48 could not 
be determined. The MLPA embB-306 probe worked in 
one of the two EMB resistant isolates; previously it was 
determined that this probe is able to detect only a pro-
portion of the mutations that can arise in the 306 codon 
of embB. As the embB gene was not sequenced, these 
results could not be confirmed. Results for INH and RIF 
related probes are shown below in comparison to the 
Genotype®MTBDRplus assay.
MLPA x MTB-DR plus - Both, the MLPA and the 
Genotype®MTBDRplus assay identified MTBC in all 
samples using the designed MTBC specific probes. 
Using DST as the reference standard, the specificity 
of MLPA and Genotype®MTBDRplus for detection of 
INH resistance was 100% [95% confidence interval 
(CI): 95-100] and 97.5% (95% CI: 91-99), respectively; 
for detection of RIF resistance was 100.0% (95% CI: 99-
100) and 98.8% (96-100), respectively. The MLPA and 
Genotype®MTBDRplus sensitivity was 92.8% (95% 
CI: 66-99) and 85.7% (95% CI: 59-97), respectively, to 
detect INH resistance; and 87.5% (95% CI: 51-99) and 
100%, (95% CI: 63-100) to detect RIF resistance (Ta-
ble III). Assuming sequencing as reference standard 
for the genotypic characterisations by the MLPA and 
Genotype®MTBDRplus methods, the sensitivity to INH 
resistance detection was 92.8%, (CI 95% 66-99) and 
85.7% (CI 95% 59-97) respectively, and the specificity 
was 100% (CI 95% 95-100) and 97.5% (CI 95% 91-99), 
respectively. In relation to RIF resistance, the sensitiv-
ity was 85.7% (CI 95% 51-99) and 100% (CI 95% 63-
100), respectively, and the specificity was 100% (CI 
95% 99-100) and 98.8% (CI 95% 96-100), respectively 
(Table IV). The agreement, measured by kappa (k) be-
tween MLPA and sequencing was the same to MLPA 
and DST: 0.95 (95% CI: 0.90 - 99) for INH and 0.92 
(95% CI: 0.86 - 0.97) for RIF, respectively. As well as, 
Genotype®MTBDRplus showed the same kappa results 
when it was compared to sequencing and to DST: K = 
0.83 (95% CI: 0.74 - 0.91) to INH and 0.93 (95% CI: 0.87 
- 0.98) to RIF (Tables III, IV).
TABLE II
Drug susceptibility testing (DST), sequencing, multiplex ligaton-dependent probe amplification (MLPA)  
and GenoType MTBDRplus results for the 96 isolates studied
No of  
samples
DST Sequencing GenoType MTBDRplus (A) MLPA (B)
INH RIF katG inhA rpoB katG inhA rpoB katG inhA rpoB
79 S S WT WT WT WT WT WT WT WT WT
4 R R S315T WT S531L S315T WT S531L S315T WT S531L
4 R S S315T WT WT S315T WT WT S315T WT WT
1 R R S315T WT D516V/H526Y/S531L WT WT H526Y/S531L WT WT S531L
1 R R S315T WT D516V/S531L S315T WT D516V S315T WT WT
1 R R S315T WT D516V/S531L S315T WT D516V S315T WT S531L
1 R S WT (-15C →T) WT WT WT WT WT (-15C →T) WT
1 S R WT WT S531L WT WT S531L WT WT S531L
1 S S WT WT WT S315T WT WT WT WT WT
1 S S WT WT WT S315T WT D516V WT WT WT
1 R S S315T WT WT S315T WT WT S315T WT WT
1 R S S315T WT WT S315T WT WT S315T WT WT
INH: isoniazid; R: resistant; RIF: rifampicin; S: susceptible; WT: wild-type.
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DISCUSSION
The currently available methods to identify M. tu-
berculosis and mutations related to drug resistance are 
mainly based on the PCR amplification of target genes 
or mutations and subsequent analysis of the amplified 
product by reverse or direct hybridisation with comple-
mentary probes, sequencing or melting point analysis. As 
a limitation, these methods do not allow multiplexing of 
many targets (the exact number depends on the thermo-
dynamic and structural characteristics of the sequences 
to be amplified) without a significant loss of specificity 
and overall accuracy (Bergval et al. 2008). An efficient 
and high-multiplex assay, able to detect several widely 
dispersed point of mutations and gene sequences involved 
in tuberculosis drug resistance and molecular typing, es-
pecially for complicated cases of TB recurrence, could 
benefit patient treatment and would be a very useful tool 
for the management of efficient TB control programs. Ge-
notyping allows distinguishing between recurrent cases 
of reinfection or reactivation (Unis et al. 2014), enabling 
molecular epidemiological studies to monitor the geno-
typic diversity of TB, as some particular genotypes are 
correlated with disease dynamics, outbreak detection and 
increased virulence (Narvskaya et al. 2002, Gomes et al. 
2012, Perizzolo et al. 2012, Dalla Costa et al. 2015).
Unless isolates are routinely typed it will not be pos-
sible to further explore these associations. Moreover, 
clinically severe cases of TB are more prevalent among 
presumed extensively drug-resistant TB (XDR-TB) cases, 
treatment dropout, and/or TB and M/XDR-TB outbreaks.
The MLPA genotype marker probes katG-463 and 
gyrA-95, specific for principal genetic group (PGG) 
one, two and three families, allow the discrimination be-
tween the different bacterial subspecies (Bergval et al. 
2008) (Table I). These results highlight the potential use 
of MLPA, as it appears ligated in all samples; however 
there were some interpretation concerns. Further stud-
ies focusing on phylogenic view should be conducted to 
better understand these results. TbD1 probe was ligated 
in most of the samples, this probe targets the TbD1 dele-
tion site and thus the presence of its product indicates the 
presence of the TbD1 deletion. As the TbD1 probe region 
is absent in modern M. tuberculosis strains (Baker et al. 
2004), it was possible to infer that most of the tested 
samples are so called “modern” strains. Additionally, the 
inclusion of only two M. tuberculosis isolates resistant to 
EMB precluded the evaluation of the EMB drug resis-
tance performance of MLPA. However, as the embB-306 
probe has previously been shown to be specific for only 
two out of the three possible mutations in this codon, 
absence of a mutation cannot be concluded from absence 
of an MLPA product (Sreevatsan et al. 1997).
Genotype®MTBDRplus has been compared to phe-
notypic and other molecular assays with very impressive 
performance and was endorsed by WHO for MDR-TB 
molecular detection in 2008 (Nikolayevsky et al. 2009, 
Ferreira Jr et al. 2014, Asante-Poku et al. 2015). Since the 
first report using MLPA as a promising alternative for 
TB genetic characterisation (Bergval et al. 2008), few 
studies evaluating MLPA in comparison to other assays 
have been described (Bergval et al. 2012, Sengstake et 
al. 2014, Chaidir et al. 2016). In this scenario, as EMB 
and PZA susceptibility testing show no reliable results, 
and having small sample size of drug-resistant M. tuber-
culosis strains, in our study we relied on the evaluation 
of MLPA performance on RIF and INH resistance.
The concordance between results of MLPA and 
sequencing (gold-standard) was slightly higher than 
Genotype®MTBDRplus versus sequencing for the assess-
ment of INH resistance. Asante-Poku et al. (2015) reported 
misdiagnosis by Genotype®MTBDRplus in approximate-
ly 16% of INH-monoresistant isolates that were wrongly 
identified as susceptible, reinforcing the possibility that 
Genotype®MTBDRplus may have limitations in the detec-
tion of INH resistance, depending on the local prevalence 
of unusual mutations. Simons et al. (2015) also reported 
low sensitivity (36%) of the Genotype®MTBDRplus in de-
tecting inhA gene mutations.
Regarding the agreement between Genotype® 
MTBDRplus and MLPA versus the standard DST (Table 
III) and sequencing (Table IV), results were very concor-
dant for INH (Kappa A = 0.83 and kappa B = 0.95) and RIF 
(Kappa A = 0.93 and kappa B = 0.92) resistance detection 
with a better performance of the MLPA assay since it was 
able to correctly detect the inhA (-15C →T) mutation re-
sponsible for the INH resistance detected by the DST assay. 
Concerning the overall distribution of mutations associated 
with INH resistance, the most frequent mutation was katG 
S315T, similarly to what has been observed by other au-
thors (Dalla Costa et al. 2009, Cambau et al. 2015).
The S531L mutation in the rpoB gene was the most fre-
quent mutation found in the RIF resistant isolates, followed 
by mutations in codon D516V, similar to that reported 
elsewhere (Perizzolo et al. 2012, Maschmann et al. 2013). 
For the detection of RIF the discrepant results occurred 
with three samples; Genotype®MTBDRplus detected one 
D516V rpoB mutation in a sample with no mutation in 
the rpoB region. Drobniewski et al. (2012) reported that 
both Genotype®MTBDRplus and GeneXpert MTB/RIF 
assays may present lower specificity for RIF resistance 
detection. MLPA was unable to detect rpoB mutations in 
one sample, maybe due to the presence of strains exhibit-
ing heteroresistance as described by other researchers on 
rpoB, D516V/S531L (Nikolayevsky et al. 2009, van Deun 
et al. 2009) (Table I). Genotype®MTBDRplus correctly 
determined RIFr but only detected the D516V mutation, 
the S531L was not detected (Table II).
MLPA allowed the identification of all the Haarlem 
genetic clade strains with the ogt-15 probe, but this test 
did not cover the T and LAM prevalent lineages of M. 
tuberculosis in Brazil, as described elsewhere (Gomes et 
al. 2012). Beijing probes are also included in this MLPA 
version, no ligation of these probes was seen in any iso-
late, in agreement with spoligotyping results.
The MLPA and Genotype®MTBDRplus speci-
ficity for detecting INH resistance was 100.0% and 
97.5% respectively; and 100.0% and 98.8% respec-
tively for detection of RIF resistance. MLPA and 
Genotype®MTBDRplus showed higher agreement with 
sequencing than DST. Overall, the MLPA performance 
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to detect drug-resistant TB and MDR-TB showed similar 
accuracy to Genotype®MTBDRplus, with the advantage 
of being easily optimised on a routine basis to address 
accurately the early detection of MDR-TB, with the pos-
sibility to expand to further drug targets and antibiotics.
In comparison to other molecular assays, MLPA is a 
test that allows adjustments in probe composition, thus 
targeted loci can be adapted to the local prevalence of 
certain mutations by a simple addition or removal of 
probes from the master mix. As a final consideration 
regarding study limitations, a limited number of clini-
cal isolates with INH and/or RIF resistance was evalu-
ated and minimal inhibitory concentration (MIC) was 
not performed. However, we observed that MLPA, and 
other truly multiplexed assays adapted to tuberculo-
sis diagnosis, can be particularly suitable for detecting 
additional drug resistance to other antimicrobials in a 
single step, being especially important in recurrence, 
treatment dropout, or presumed XDR-TB for a rapid and 
proper treatment decision. Moreover, MLPA may allow 
complementation to the diagnosis with epidemiologi-
cal M. tuberculosis lineages information to monitor the 
DR/MDR-TB burden and evolution in different regions, 
especially in regions where routine drug susceptibility 
testing is not implemented in laboratories and where the 
rates of M/XDR-TB is suspected to be high. The flex-
ibility and specificity of MLPA, demonstrated above, 
along with its ability to simultaneously genotype and 
detect drug resistance mutations, make MLPA an easy 
to implement and very important molecular tool for in-
creased drug resistance coverage and early detection of 
M/XDR-TB as recommended by WHO and the Brazil-
ian Ministry of Health (MS 2010, WHO 2015).
Ethics approval - The study was approved by the 
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